We have observed
1 EP application
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after May 25, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF EPSILON-POLY-L-LYSINE FOR INCREASING THE BIOAVAILABILITY OF ANTIMICROBIAL PEPTIDES IN THE HUMAN SKIN